Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect on Glycemic Control of Individual Maximum Effective Dose of NNC 90-1170 as Add on Therapy to Metformin Compared to Monotherapy of NNC 90-1170 or Metformin or a Metformin-SU Combination Therapy in Patients With Type 2 Diabetes. A Double-blind, Double-dummy, Randomised, Parallel-group, Dose Titration Study With an Open Labelled OHA Arm

NCT01511172 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT01511172
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01511172 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect on Glycemic Control of Individual Maximum Effective Dose of NNC 90-1170 as Add on Therapy to Metformin Compared to Monotherapy of NNC 90-1170 or Metformin or a Metformin-SU Combination Therapy in Patients With Type 2 Diabetes. A Double-blind, Double-dummy, Randomised, Parallel-group, Dose Titration Study With an Open Labelled OHA Arm
Lead sponsor
Novo Nordisk A/S
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2002
Completion date
December 31, 2002
Enrollment
145 (actual)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes, diabetes mellitus, type 2